Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results

Core Viewpoint - Analysts remain optimistic about Sagimet Biosciences Inc. (SGMT), with 91% maintaining a bullish outlook and a consensus price target of $27.50, indicating a potential upside of 437.27% [1][2]. Financial Performance - Sagimet Biosciences concluded 2025 with $113.1 million in cash, $39.1 million in R&D costs, and a net loss of $51.0 million, compared to a $45.6 million loss in 2024 [3]. Pipeline Developments - The company plans to initiate a Phase 2 trial in F4 MASH patients in the second half of 2026, following the successful completion of a Phase 1 pharmacokinetic trial for denifanstat combined with resmetirom, which showed no significant adverse effects [2][4]. - Sagimet is also progressing with its first-in-human Phase 1 trial for TVB-3567, targeting acne, while its partner Ascletis has published positive Phase 3 acne data and received NDA acceptance in China [3][4]. Analyst Ratings - HC Wainwright reaffirmed its "Buy" rating for Sagimet Biosciences, reflecting confidence in the stock's potential [4].